AstraZeneca to bolster US footprint with multi-billion dollar strategy
In a bold move set to reshape the pharmaceutical landscape, AstraZeneca has announced a substantial $3.5 billion investment aimed at expanding its research and manufacturing ... Read More
Danaher wraps up $5.7bn acquisition of Abcam to bolster life sciences segment
Danaher Corporation (NYSE: DHR), a renowned global science and technology innovator, has announced the completion of its acquisition of Abcam plc (NASDAQ: ABCM), a key ... Read More
Danaher to acquire protein consumables supplier Abcam for $5.7bn
Danaher Corporation (NYSE: DHR), a global science and technology innovator, has announced a definitive agreement to acquire Abcam plc (NASDAQ: ABCM), a leading global supplier ... Read More
Boston mass shooting sends shockwaves, seven hospitalized amid Caribbean festival
In a horrifying turn of events that has shattered the city's festive spirit, at least seven people have been rushed to the hospital following a ... Read More
Microbiome company Vedanta Biosciences raises $68m in Series D
Vedanta Biosciences, a clinical-stage microbiome company founded by PureTech Health, has raised $68 million in a Series D financing round led by affiliates of Magnetar ... Read More
Nipocalimab developer Momenta Pharmaceuticals to be acquired by J&J
J&J acquisition of Momenta Pharmaceuticals : US healthcare giant Johnson & Johnson (J&J) has signed a $6.5 billion deal to acquire Momenta Pharmaceuticals, a biotech ... Read More
Precision oncology company Black Diamond Therapeutics raises $85m
Black Diamond Therapeutics, a precision oncology company based in Cambridge, has raised $85 million from a Series C financing round led by Boxer Capital of ... Read More
Pandion bags $795m deal with Astellas for pancreas-targeted immunomodulators
Pandion Therapeutics has bagged a $795 million worth license and collaboration deal with Japanese pharma company Astellas Pharma for the research, development, and commercialization of ... Read More
Twentyeight-Seven Therapeutics launches with $65m to develop RNA-modulating cancer therapies
In an ambitious move within the biotechnology sector, a new U.S. biotech company, Twentyeight-Seven Therapeutics (28-7), has been established in Cambridge with a primary focus ... Read More